Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors
Top Cited Papers
Open Access
- 18 June 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1608401
Abstract
The global market for therapeutic peptides is projected to continue to grow at a fast pace in the coming years in response to high demand for these products. The increasing complexity of chemical and recombinant peptide manufacturing processes may impact product quality attributes, including as related to immunogenicity risk. While it is well established that product-related factors, including impurities, can impact the immunogenicity of a biologic product, assessing the actual impact of a specific product quality attribute on immunogenicity is difficult. Despite significant advances in the analytical characterization of complex peptide products, gaps still exist in our understanding of the significance of impurities to the overall peptide immunogenicity risk, and questions remain about what the best-suited control strategies are. These gaps have the largest impact on the assessment of immunogenicity risk of follow-on therapeutic peptide products, when clinical data are not available to inform that risk. Current regulatory guidance on impurity qualification thresholds is sparse, and in vitro and in silico immunogenicity assessment methods for evaluating the immunogenicity risk of impurities present technical and methodological limitations. We highlight these challenges and offer points to consider for handling them.Keywords
This publication has 27 references indexed in Scilit:
- FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyondJournal of Peptide Science, 2024
- A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the ClinicPharmaceutical Research, 2024
- Immunogenicity risk assessment of synthetic peptide drugs and their impuritiesDrug Discovery Today, 2023
- Recent advances in the development of therapeutic peptidesTrends in Pharmacological Sciences, 2023
- Trends in peptide drug discoveryNature Reviews Drug Discovery, 2021
- Human skin explant model for the investigation of topical therapeuticsScientific Reports, 2020
- Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptidesInternational Journal of Pharmaceutics, 2017
- Immunogenicity of Therapeutic Proteins: The Use of Animal ModelsPharmaceutical Research, 2011
- Impact of Product-Related Factors on Immunogenicity of BiotherapeuticsJournal of Pharmaceutical Sciences, 2011
- Immunological substance testing on human lymphatic micro-organoids in vitroJournal of Biotechnology, 2010